Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - alimemazine tartrate 0.6%{relative};  ; alimemazine tartrate 0.6%{relative} - syrup - 30 mg/5ml - active: alimemazine tartrate 0.6%{relative}   excipient: ascorbic acid citric acid as monohydrate ethanol prunus armeniaca purified water sodium benzoate sodium citrate dihydrate sodium metabisulfite sodium sulfite sucrose active: alimemazine tartrate 0.6%{relative} excipient: ascorbic acid citric acid monohydrate ethanol prunus armeniaca purified water sodium benzoate sodium citrate dihydrate sodium metabisulfite sodium sulfite sucrose - · urticaria

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus haemagglutinin 15ug (a h1n1 - strain to be confirmed prior to marketing); influenza virus type a haemagglutinin 15ug (h3n2 - strain to be confirmed prior to marketing); influenza virus type b haemagglutinin 15ug (strain to be confirmed prior to marketing) - suspension for injection - 15 mcg - active: influenza virus haemagglutinin 15ug (a h1n1 - strain to be confirmed prior to marketing) influenza virus type a haemagglutinin 15ug (h3n2 - strain to be confirmed prior to marketing) influenza virus type b haemagglutinin 15ug (strain to be confirmed prior to marketing) excipient: dibasic sodium phosphate dihydrate hydrochloric acid monobasic potassium phosphate potassium chloride sodium chloride sodium hydroxide water for injection

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - influenza virus a/hong kong/4801/2014 (h3n2) - like strain 15ug (a/ hong kong/4801/2014 nymc x-263b );  ; influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/michigan/45/2015 nymc x-275);  ; influenza virus b/brisbane/60/2008 - like strain 15ug (b/brisbane/60/2008 );   - solution for injection - 0.5 ml - active: influenza virus a/hong kong/4801/2014 (h3n2) - like strain 15ug (a/ hong kong/4801/2014 nymc x-263b )   influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/michigan/45/2015 nymc x-275)   influenza virus b/brisbane/60/2008 - like strain 15ug (b/brisbane/60/2008 )   excipient: dibasic sodium phosphate dihydrate monobasic potassium phosphate neomycin potassium chloride sodium chloride water for injection - vaxigrip is indicated for the prevention of influenza caused by influenza virus types a and b in adults and children aged 6 months and over.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - neisseria meningitidis group a polysaccharide 50ug; neisseria meningitidis group c polysaccharide 50ug; neisseria meningitidis group w135 polysaccharide 50ug; neisseria meningitidis group y polysaccharide 50ug - injection with diluent - 0.5 ml - active: neisseria meningitidis group a polysaccharide 50ug neisseria meningitidis group c polysaccharide 50ug neisseria meningitidis group w135 polysaccharide 50ug neisseria meningitidis group y polysaccharide 50ug excipient: lactose monohydrate sodium chloride purified water - menomune® acyw-135 is indicated for active immunisation of adults and children older than 2 years against disease caused by neisseria meningitidis groups a, c, y and w-135, the major manifestation being meningococcal meningitis. vaccination may be considered for the following individuals: · travellers to countries recognised as having highly endemic or epidemic disease. · control of epidemics of infection caused by neisseria meningitidis groups a, c, y and w-135 in confined communities. · individuals at particular high risk of acquiring meningococcal infection, including persons with anatomic or functional asplenia. · close contacts of persons with meningococcal disease due to groups a, c, y and w-135, as an adjunct to appropriate chemoprophylaxis.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - tiaprofenic acid 200mg - tablet - 200 mg - active: tiaprofenic acid 200mg

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - tiaprofenic acid 300mg - tablet - 300 mg - active: tiaprofenic acid 300mg

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - promethazine hydrochloride 1 mg/ml - elixir - 0.1% w/v - active: promethazine hydrochloride 1 mg/ml excipient: acesulfame potassium ascorbic acid caramel citric acid monohydrate hydrogenated glucose syrup orange flavour juice 510844e purified water sodium benzoate sodium citrate dihydrate sodium metabisulfite sodium sulfite - allergies: treatment of allergic conditions including some allergic reactions to drugs, urticaria and allergic contact dermatitis, and allergic reactions to insect bites and stings. upper respiratory tract: relief of excessive secretion in the upper respiratory tract as a result of hayfever and allergic rhinitis. nausea and vomiting: antiemetic for vomiting from various causes, including postoperative vomiting, irradiation sickness, drug induced nausea and motion sickness. sedation: for short term use under the advice of a doctor or pharmacist. do not use for more than 7 to 10 consecutive days. other: promethazine has sedative effects and can be used in the symptomatic management of measles and chicken pox. promethazine can be used as a preanaesthetic medication for the prevention and control of post operative vomiting.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - capecitabine 150mg - film coated tablet - 150 mg - active: capecitabine 150mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose   iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose purified talc purified water   titanium dioxide - capecitabine winthrop is indicated for the treatment of patients with locally advanced or / metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine winthrop in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - capecitabine 500mg - film coated tablet - 500 mg - active: capecitabine 500mg excipient: colloidal silicon dioxide croscarmellose sodium hypromellose   iron oxide red iron oxide yellow macrogol 400 magnesium stearate microcrystalline cellulose purified talc purified water   titanium dioxide - capecitabine winthrop is indicated for the treatment of patients with locally advanced or / metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen unless therapy with these and other standard agents are clinically contraindicated. capecitabine winthrop in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - asparaginase 10000 [iu] (derived from cultures of e.coli hap ex japan, expressed as 10,000ku) - powder for injection - 10,000ku - active: asparaginase 10000 [iu] (derived from cultures of e.coli hap ex japan, expressed as 10,000ku) - treatment of acute lymphoblastic leukaemia